<HashMap><database>EVA</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Vcf>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/Control1.vcf.gz</Vcf><Vcf>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/CKD_Patient1.vcf.gz</Vcf><Vcf>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/CKD_Patient1.vcf.gz.csi</Vcf><Vcf>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/Control1.vcf.gz.csi</Vcf><Vcf>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/CKD_Patient.vcf.gz.csi</Vcf><Vcf>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/Control.vcf.gz.csi</Vcf><Vcf>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/Control.vcf.gz</Vcf><Vcf>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/CKD_Patient.vcf.gz</Vcf><Other>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/CKD_Patient.vcf.csi</Other><Other>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/CKD_Patient1.vcf.csi</Other><Other>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/Control.vcf.csi</Other><Other>ftp://ftp.ebi.ac.uk/pub/databases/eva/PRJNA1348893/Control1.vcf.csi</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><dataset_type>Exome Sequencing</dataset_type><omics_type>Genomics</omics_type><submitter>Misr University for Science and Technology (MUST)</submitter><instrument_platform>Illumina NovaSeq 6000</instrument_platform><species>Homo Sapiens</species><full_dataset_link>https://www.ebi.ac.uk/eva/?eva-study=PRJNA1348893</full_dataset_link><repository>EVA</repository></additional><is_claimable>false</is_claimable><name>Genetic Analysis in Patients with Chronic Kidney Disease (CKD) and Healthy Controls</name><description>This project involves Whole Exome Sequencing (WES) of human samples obtained from individuals diagnosed with Chronic Kidney Disease (CKD) and matched healthy control subjects. The goal of the study is to identify potentially pathogenic genetic variants that may contribute to CKD susceptibility, disease progression, and clinical phenotype variation. Comparative analysis between the CKD group and healthy controls enables the detection of disease-associated variants, rare mutations, and disrupted gene pathways.</description><dates><publication>2025-11-06</publication></dates><accession>PRJNA1348893</accession><cross_references><TAXONOMY>9606</TAXONOMY></cross_references></HashMap>